Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of IAC versus IA induction regimens in newly treated acute myeloid leukemia
ChiCTR-IPR-14005466Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cladribine, idarubicin and cytarabine in acute myeloid leukemia (AML) (3 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete remission rate. Planned start Nov 2014; status: not yet recruiting.
02
Drugs
cladribineidarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IPR-14005466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005466.